These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31122820)

  • 1. Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?
    Bagante F; Ruzzenente A; Conci S; Rusev BC; Simbolo M; Campagnaro T; Pawlik TM; Luchini C; Iacono C; Scarpa A; Guglielmi A
    HPB (Oxford); 2019 Dec; 21(12):1648-1655. PubMed ID: 31122820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.
    Ma B; Meng H; Tian Y; Wang Y; Song T; Zhang T; Wu Q; Cui Y; Li H; Zhang W; Li Q
    BMC Cancer; 2020 Apr; 20(1):318. PubMed ID: 32293336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.
    Simbolo M; Fassan M; Ruzzenente A; Mafficini A; Wood LD; Corbo V; Melisi D; Malleo G; Vicentini C; Malpeli G; Antonello D; Sperandio N; Capelli P; Tomezzoli A; Iacono C; Lawlor RT; Bassi C; Hruban RH; Guglielmi A; Tortora G; de Braud F; Scarpa A
    Oncotarget; 2014 May; 5(9):2839-52. PubMed ID: 24867389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
    Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
    Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
    Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
    Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort.
    Jansson H; Cornillet M; Björkström NK; Sturesson C; Sparrelid E
    Eur J Surg Oncol; 2020 May; 46(5):804-810. PubMed ID: 31848078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss.
    Misumi K; Hayashi A; Shibahara J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M
    Histopathology; 2017 Apr; 70(5):766-774. PubMed ID: 27864835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
    Lowery MA; Ptashkin R; Jordan E; Berger MF; Zehir A; Capanu M; Kemeny NE; O'Reilly EM; El-Dika I; Jarnagin WR; Harding JJ; D'Angelica MI; Cercek A; Hechtman JF; Solit DB; Schultz N; Hyman DM; Klimstra DS; Saltz LB; Abou-Alfa GK
    Clin Cancer Res; 2018 Sep; 24(17):4154-4161. PubMed ID: 29848569
    [No Abstract]   [Full Text] [Related]  

  • 9. Mutational spectrum and precision oncology for biliary tract carcinoma.
    Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H
    Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015
    [No Abstract]   [Full Text] [Related]  

  • 10. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
    Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
    Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Approach to Quantify Heterogeneity of Intrahepatic Cholangiocarcinoma: The Hidden-Genome Classifier.
    Song Y; Boerner T; Drill E; Shin P; Kumar S; Sigel C; Cercek A; Kemeny N; Abou-Alfa G; Iacobuzio-Donahue C; Cowzer D; Schultz N; Walch H; Balachandran V; Groot Koerkamp B; Kingham P; Soares K; Wei A; D'Angelica M; Drebin J; Chandwani R; Harding JJ; Jarnagin W
    Clin Cancer Res; 2024 Aug; 30(16):3499-3511. PubMed ID: 38864854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers.
    Liao H; Chen X; Wang H; Lin Y; Chen L; Yuan K; Liao M; Jiang H; Peng J; Wu Z; Huang J; Li J; Zeng Y
    Cancer Res; 2024 Jun; 84(11):1747-1763. PubMed ID: 38471085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.
    Jiao Y; Pawlik TM; Anders RA; Selaru FM; Streppel MM; Lucas DJ; Niknafs N; Guthrie VB; Maitra A; Argani P; Offerhaus GJA; Roa JC; Roberts LR; Gores GJ; Popescu I; Alexandrescu ST; Dima S; Fassan M; Simbolo M; Mafficini A; Capelli P; Lawlor RT; Ruzzenente A; Guglielmi A; Tortora G; de Braud F; Scarpa A; Jarnagin W; Klimstra D; Karchin R; Velculescu VE; Hruban RH; Vogelstein B; Kinzler KW; Papadopoulos N; Wood LD
    Nat Genet; 2013 Dec; 45(12):1470-1473. PubMed ID: 24185509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.
    Zhu AX; Borger DR; Kim Y; Cosgrove D; Ejaz A; Alexandrescu S; Groeschl RT; Deshpande V; Lindberg JM; Ferrone C; Sempoux C; Yau T; Poon R; Popescu I; Bauer TW; Gamblin TC; Gigot JF; Anders RA; Pawlik TM
    Ann Surg Oncol; 2014 Nov; 21(12):3827-34. PubMed ID: 24889489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological features and prognosis of advanced biliary carcinoma centered in the cystic duct.
    Nakanishi Y; Tsuchikawa T; Okamura K; Nakamura T; Noji T; Asano T; Tanaka K; Shichinohe T; Mitsuhashi T; Hirano S
    HPB (Oxford); 2018 Jan; 20(1):28-33. PubMed ID: 28890312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of short- and long-term outcomes between anatomical subtypes of resected biliary tract cancer in a Western high-volume center.
    Roos E; Strijker M; Franken LC; Busch OR; van Hooft JE; Klümpen HJ; van Laarhoven HW; Wilmink JW; Verheij J; van Gulik TM; Besselink MG
    HPB (Oxford); 2020 Mar; 22(3):405-414. PubMed ID: 31494056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways.
    Chen XX; Yin Y; Cheng JW; Huang A; Hu B; Zhang X; Sun YF; Wang J; Wang YP; Ji Y; Qiu SJ; Fan J; Zhou J; Yang XR
    Cell Death Dis; 2018 Oct; 9(10):1036. PubMed ID: 30305612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated hypermethylation at selective genes and their clinicopathological features.
    Lee K; Song YS; Shin Y; Wen X; Kim Y; Cho NY; Bae JM; Kang GH
    Sci Rep; 2020 Sep; 10(1):15820. PubMed ID: 32978444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
    Borger DR; Tanabe KK; Fan KC; Lopez HU; Fantin VR; Straley KS; Schenkein DP; Hezel AF; Ancukiewicz M; Liebman HM; Kwak EL; Clark JW; Ryan DP; Deshpande V; Dias-Santagata D; Ellisen LW; Zhu AX; Iafrate AJ
    Oncologist; 2012; 17(1):72-9. PubMed ID: 22180306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
    Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
    JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.